Business context and reporting period
Nova Measuring Instruments Ltd. filed this Form 20-F for the fiscal year ended December 31, 2016. It designs and sells metrology and process-control systems and related services for semiconductor manufacturing. The filing reports annual results; it does not provide clear standalone fourth-quarter financial statements or a complete Q4-versus-prior-year-quarter comparison.
Amounts below are U.S. dollars; financial statement amounts are in millions unless noted. The company reports under U.S. GAAP. Independent auditors issued unqualified opinions on the financial statements and on internal control over financial reporting.
Financial performance and position
| Metric | 2016 | 2015 | Change or context |
|---|---|---|---|
| Revenue | $163.9 | $148.5 | Up 10% |
| Product revenue | $122.4 | $111.2 | Up 10% |
| Service revenue | $41.5 | $37.3 | Up 11%; record service revenue |
| Gross profit / margin | $75.3 / 45.9% | $77.1 / 51.9% | Lower; 2016 included a $12.9 million OCS royalty buyout expense |
| Operating income / margin | $10.2 / 6.2% | $11.6 / 7.8% | Down 12% |
| Net income / margin | $9.6 / 5.9% | $15.7 / 10.6% | Down 39%; tax expense replaced a tax benefit |
| Diluted EPS | $0.35 | $0.57 | Down 39% |
| Cash from operations | $(4.2) | $25.8 | Decline reflected the royalty payment and higher receivables |
| Cash, cash equivalents and bank deposits | $91.7 | $97.8 | Down about $6.1 million |
| Working capital | $128.9 | $112.8 | Up about $16.1 million |
| Total assets / shareholders’ equity | $218.6 / $174.7 | $207.3 / $161.1 | Both increased |
There was no significant long-term debt. Year-end trade receivables rose to $42.6 million from $19.0 million, primarily reflecting higher fourth-quarter sales and shipment timing. Inventory was $29.3 million, versus $27.7 million. Capital expenditures were $3.1 million; management expected approximately $8 million in 2017.
Material changes versus prior periods
- Revenue reached a fourth consecutive annual record. Management attributed 2016 growth to stronger product demand, particularly optical critical-dimension products, and higher service revenue from a larger installed base. XPS revenue also benefited from including ReVera for a full year, compared with nine months in 2015.
- Reported gross profit declined despite revenue growth, principally because cost of revenue included the $12.9 million OCS buyout expense. Inventory write-offs were $4.0 million in 2016, compared with $2.6 million in 2015.
- Net R&D expense fell 12% to $35.0 million, partly because R&D grants increased to $4.3 million from $1.2 million. Sales and marketing expense rose 35% to $21.5 million, while general and administrative expense fell 20% to $6.8 million, largely as 2015 included ReVera acquisition and integration costs.
- Income taxes were $1.7 million of expense in 2016, compared with a $3.5 million benefit in 2015. The filing cites reduced accumulation of R&D credits and the end of certain Israeli tax exemptions.
- China represented 19% of revenue by installation location, up from 6% in 2015; Taiwan remained the largest location at 45%. The five largest customers contributed 76% of revenue, and the largest customer alone accounted for 34%.
Outlook, risks and unusual items
- Management expected semiconductor capital spending and wafer-fab-equipment spending to increase in 2017. Cited industry forecasts were 7.2% growth in semiconductor revenue and 5.7% growth in wafer-fab-equipment sales. These are industry forecasts, not company revenue guidance; the filing gives no specific 2017 revenue or earnings target.
- Management’s priorities included developing products for advanced logic and memory nodes, expanding optical and X-ray metrology, growing software offerings, and continuing ReVera integration and customer collaboration. It expected higher aggregate operating expenses in 2017 than in 2016 and believed available cash would fund planned activities for at least 12 months.
- The $12.9 million OCS royalty buyout settled a contingent net royalty obligation reported at approximately $24.3 million. Nova said it had no remaining royalty liability for the prior grants, except potential royalties if certain projects previously declared failed are commercialized; management did not anticipate revenue from those projects.
- Key risks include semiconductor-industry cyclicality, dependence on a small number of customers and three principal product lines, rapid technological change, competition, reliance on process-equipment partners and limited suppliers, and single manufacturing facilities for each product group. International sales, Israeli operating exposure, foreign exchange, tax treatment and concentration of cash at banks are also risks. More than 40% of cash reserves were held at one institution.
- As of December 31, 2016, management and the auditor concluded internal controls over financial reporting were effective. Separately, the filing disclosed that a U.S. subsidiary employee filed an overtime collective-action complaint on February 20, 2017; Nova had not been served as of the filing date.
- The company stated it did not expect to pay cash dividends for at least several years. It also stated it believed it was not a PFIC for 2016 and expected not to be one in 2017, but cautioned that the determination is uncertain and may be challenged.
Important facts for investors to verify
- Whether the $12.9 million OCS settlement and elevated inventory write-offs are non-recurring, and how gross margins develop after those items.
- Whether the sharp increase in receivables converts to cash, and whether operating cash flow returns to positive levels.
- Customer concentration and the largest customer’s 34% revenue share, including the sensitivity of orders to customer investment cycles.
- Execution against 2017 spending expectations, the planned $8 million of capital expenditures, and management’s expectation of higher operating expenses.
- Cash exposure to individual banks, the impact of currency movements despite hedging, and any developments in the disclosed overtime complaint or OCS/NATI obligations.
- Potential shareholder dilution from outstanding options and restricted stock units, and the implications of the board’s approval of the compensation policy after shareholders rejected it.